subject area of
- Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy Academic Article
- Cannabinoid WIN55212‐2 impairs peanut‐allergic sensitization and promotes the generation of allergen‐specific regulatory T cells Academic Article
- Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis Academic Article
- Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study Academic Article
- Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals Academic Article
- Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals Academic Article
- Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study Academic Article
- Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C Academic Article
- Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes Academic Article
- Physiological evidence of a postsynaptic inhibition of the tail flick reflex by a cannabinoid receptor agonist Academic Article
- Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts Academic Article
- Therapy with Efavirenz plus Indinavir in Patients with Extensive Prior Nucleoside Reverse‐Transcriptase Inhibitor Experience: A Randomized, Double‐Blind, Placebo‐Controlled Trial Academic Article